Welcome to our dedicated page for ASP Isotopes news (Ticker: ASPI), a resource for investors and traders seeking the latest updates and insights on ASP Isotopes stock.
ASP Isotopes Inc. develops isotope enrichment technologies and related critical-materials businesses for nuclear medicine, next-generation semiconductors, nuclear energy and helium markets. Company news commonly covers its Aerodynamic Separation Process and Quantum Enrichment platforms, enrichment facilities in Pretoria, South Africa, and target isotopes such as Silicon-28, Carbon-14 and Ytterbium-176.
Recurring updates also address PET Labs radiopharmaceutical operations, Quantum Leap Energy nuclear fuel-cycle initiatives, lithium laser enrichment research, Renergen and the Virginia Gas Project, material agreements, governance matters, capital-structure disclosures, and operating and financial results.
ASP Isotopes (NASDAQ: ASPI) announced a supply contract for its largest quantity of enriched silicon-28 to date, with deliveries expected in Q1 2026, and the acquisition of an independent radiopharmacy in Florida, US to expand PET Labs' operations outside South Africa.
The Florida site currently offers SPECT; PET services are expected to start in 2027. The acquisition is described as accretive to 2026 revenues, EBITDA and EPS. PET Labs is pursuing further U.S. expansion and has a non-binding term sheet for another acquisition. An investor access event is scheduled for Nov 12-13, 2025. The company also granted a 30,000-share restricted stock inducement vesting semi-annually over four years.
ASP Isotopes (NASDAQ: ASPI) will host an Institutional Investor Access Event in South Africa from November 11–13, 2025, with a possible optional visit to the Renergen Virginia Gas Project on November 14, 2025 (subject to numbers).
Limited places remain. Attendees cover their own flight and hotel costs. The agenda includes scientific sessions, plant tours of three enrichment production plants and PET Labs, management and scientific-team presentations, and Q&A. Suggested travel timing enables U.S. departures on Nov 10 (evening) and return Nov 14 (morning).
Register by emailing vpetkov@aspisotopes.com. Attendees must submit a copy of their passport by October 21, 2025 for required security clearances; registrations are subject to availability and company acceptance.
ASP Isotopes (NASDAQ:ASPI) has secured a purchase order from a U.S.-based customer for enriched Barium-137, scheduled for delivery in Q1 2026. The isotope is crucial for ion-trap quantum computing, offering a stable qubit platform and improved operational reliability for quantum processors.
Enriched Barium-137's favorable optical properties, operating in visible-light wavelengths, facilitate integration with existing hardware and support quantum networking developments. The company positions this achievement as part of its strategy to become a leading supplier of advanced materials to the quantum computing industry, alongside other industrial isotopes like Silicon-28.
ASP Isotopes (NASDAQ:ASPI), an advanced materials company focused on isotope production, announced significant leadership changes effective October 1, 2025. Founder and CEO Paul Mann will transition to Executive Chairman and take a temporary health-related leave, following complications from orthopedic surgery. Robert Ainscow, the company's COO, has been appointed Interim CEO.
Additionally, Michael Cunniffe will join Quantum Leap Energy LLC as CFO, preparing for its upcoming public listing. The company also announced two investor events: an Institutional Investor Access Event in South Africa on November 12-13, 2025, and a Quarterly Business Update webinar in November 2025.
ASP Isotopes (NASDAQ:ASPI) has appointed nuclear industry veteran Ralph L. Hunter, Jr. to its board of directors and to the board of managers of Quantum Leap Energy LLC. Hunter brings over 30 years of nuclear power industry experience in leadership roles and significant expertise in nuclear technology development.
Hunter's impressive background includes serving as Chair of the US Civil Nuclear Trade Advisory Committee (CINTAC), board membership at Rolls-Royce SMR Limited, and leadership positions at Constellation Energy. He currently serves as Chairman and CEO of RC Nuclear Consultants, LLC, which he established in June 2025.
The appointment aligns with ASP Isotopes's plans to apply its enrichment technologies to uranium production for next-generation nuclear reactors.
ASP Isotopes (NASDAQ:ASPI) has achieved significant milestones, transitioning from R&D to commercial operations with three operational isotope enrichment facilities. The company has successfully shipped its first Ytterbium-176 and Silicon-28 samples to customers, projecting $50-70 million in potential revenues for 2026-2027 from these isotopes alone.
Key developments include: Quantum Leap Energy's planned Q4 2025 IPO, a strategic MOU with Fermi America for nuclear fuel facilities, PET Labs' record-breaking performance, and the anticipated Renergen merger closing in Q3 2025. The company has expanded its management team to over 170 employees and targets $300 million in EBITDA by 2030. Additionally, ASPI recently listed on the Johannesburg Stock Exchange (JSE: ISO) to enhance liquidity and access capital markets.
[ "Successfully shipped first Ytterbium-176 and Silicon-28 samples with $50-70M potential revenue for 2026-2027", "Three isotope enrichment facilities now operational with four new laser plants planned", "Strategic MOU with Fermi America for nuclear fuel facilities development", "PET Labs achieving record performance with second cyclotron operational", "Renergen merger expected to be highly accretive to revenue, EBITDA, and EPS in 2026", "Management projects $300M EBITDA target by 2030", "Institutional ownership increased to over 70%", "Successful dual-listing on Johannesburg Stock Exchange" ]ASP Isotopes (NASDAQ:ASPI) hosted South African investors ahead of its secondary listing on the Johannesburg Stock Exchange (JSE), scheduled for August 27, 2025. The company provided significant updates on multiple isotope production facilities:
The company has shipped its first Silicon-28 samples to a US customer and expects to complete Ytterbium-176 enrichment in August 2025. Their Ytterbium facility is achieving a 52x enrichment factor, though facing a 3-4 week delay in transitioning to semi-continuous processing. The Carbon-14/12 facility is now producing 99.99% enriched Carbon-12, with first commercial delivery expected in September 2025.
Additionally, ASP Isotopes continues to progress on two major corporate initiatives: the planned spin-out of Quantum Leap Enrichment (QLE) in H2 2025 and the anticipated closure of the Renergen acquisition in Q3 2025.
ASP Isotopes (NASDAQ: ASPI) has signed a Memorandum of Understanding (MOU) with Fermi America to explore developing a High Assay Low Enriched Uranium (HALEU) enrichment facility in Carson County, Texas. The facility will utilize advanced laser-based isotope separation technology through ASPI's subsidiary Quantum Leap Energy LLC.
The project aims to strengthen U.S. nuclear fuel supply chains and reduce dependence on Russian enrichment. The facility will be located at Fermi America's 11 GW private grid campus, which includes four AP1000® nuclear units. According to the U.S. Department of Energy, HALEU demand could exceed 50 metric tons annually by 2035 in the United States alone.
ASP Isotopes (NASDAQ:ASPI) and its subsidiary Quantum Leap Energy (QLE) have entered into a strategic MOU with Fermi America to develop advanced nuclear fuel facilities at the planned 11GW HyperGrid Campus in Texas. The partnership includes two key components: a joint venture between QLE and Fermi America for HALEU nuclear fuel production, and a separate facility for ASPI to produce stable isotopes and advanced materials.
The HyperGrid Campus, co-founded by former U.S. Energy Secretary Rick Perry, will be located near the DOE's Pantex Plant in Carson County. The project aims to become the world's largest hybrid energy and data infrastructure campus, with construction starting in 2027 and the first reactor operational by 2032.
QLE has received significant interest from potential customers, with projected HALEU demand of over $37 billion through 2037. This Texas facility would be QLE's second HALEU production site, complementing their planned South African facility supporting TerraPower's Natrium project.
ASP Isotopes (NASDAQ:ASPI) has received approval for a dual listing on the Johannesburg Stock Exchange (JSE), expected to commence on August 27, 2025. The company will maintain its primary Nasdaq listing while trading on JSE's Main Board under the code "ISO".
This announcement follows ASPI's May 2025 plan to acquire Renergen Limited through a scheme arrangement where Renergen shareholders will receive 0.09196 ASPI shares per Renergen share. The acquisition, supported by 99.8% of Renergen shareholders, aims to create a global critical materials leader and is expected to close in Q3 2025.
The combined entity targets over $300 million in EBITDA by 2030, driven by isotopes, helium, and LNG sales. The transaction is projected to be highly accretive to ASPI's revenue, EBITDA, and earnings per share in 2026.